Cathie Wood's ARK buys Guardant Health, sells Adaptive Biotechnologies stock

On June 2nd, 2025, ARK ETFs, led by Cathie Wood, significantly increased their position in Guardant Health (GH) with ARKK purchasing $6.45M worth of shares, while ARKG increased its position in Illumina (ILMN) with a $4.34M purchase and 10X Genomics Inc (TXG) with a combined total of $3.19M purchase. Conversely, ARKG reduced its stake in Adaptive Biotechnologies (ADPT) by $2.65M, while ARKK decreased its position in Roblox (RBLX) by $4.82M, Palantir (PLTR) by $2.3M and Tesla (TSLA) by $552,257, signaling a portfolio realignment across healthcare, technology, and aerospace sectors.

Analysis

ARK Investment Management's daily trades on June 2nd, 2025, reveal significant strategic reallocations, underscoring a continued focus on genomics and precision oncology while reducing exposure to certain technology and biotech names. The ARKK ETF made a substantial $6.45 million investment in Guardant Health (GH), signaling strong conviction in the precision oncology firm, a sentiment supported by GH's high positive ticker sentiment score of 0.8. Similarly, the ARKG ETF reinforced its commitment to the genomics sector by acquiring $4.34 million in Illumina (ILMN) and, alongside ARKK, collectively purchased $3.19 million of 10X Genomics (TXG) stock; this pattern of consistent buying in TXG, which has a ticker sentiment of 0.9, indicates a bullish outlook on the life sciences technology company. The ARKF ETF also increased its fintech exposure with a $1.51 million purchase of eToro Group (ETOR). Conversely, ARKG continued its divestment from Adaptive Biotechnologies (ADPT) with a $2.65 million sale, a trend possibly indicating a strategic shift away from the firm, which registered a negative ticker sentiment of -0.8. ARKK notably reduced positions in technology, selling $4.82 million of Roblox (RBLX), $2.3 million of Palantir (PLTR), and $552,257 of Tesla (TSLA), alongside ARKF trimming $1.5 million from CrowdStrike (CRWD), with these divested stocks generally showing negative sentiment scores. The ARKX ETF diversified its aerospace holdings with a $1.44 million investment in L3Harris Technologies (LHX) while divesting $1.46 million from Trimble (TRMB). These transactions highlight dynamic portfolio management aimed at capitalizing on perceived growth opportunities and adjusting risk exposure across innovative sectors.

Key Decisions for Investors

• Investors should consider ARK's strong buying activity and capital allocation towards Guardant Health, Illumina, and 10X Genomics as indicative of high conviction in the growth potential of the precision oncology and genomics sectors.
• The significant sales of Adaptive Biotechnologies, Roblox, Palantir, Tesla, and CrowdStrike warrant attention, as they may signal ARK's revised outlook or risk assessment for these specific companies.
• Monitoring ARK's daily trading patterns can provide valuable insights into emerging sector preferences and potential shifts in sentiment regarding disruptive innovation themes, guiding strategic portfolio adjustments.